Spirit Scientific (7790) presented its “PLTgel”, a gel-form, high-concentration platelet lyophilized (PLT) slow-release preparation service, at the 2025 Taiwan Association of Rehabilitation Medicine Annual Meeting. This innovative solution targets the clinical needs of rehabilitation and sports medicine by offering a novel, long-acting repair option.
Unlike liquid PLT or traditional Platelet-Rich Plasma (PRP), PLTgel’s gel-like consistency is better suited for large-area soft tissue injuries, including cartilage, muscle, tendon, and ligament tears or defects, as well as degenerative arthritis. Physicians at the conference highlighted its enhanced adhesion to the affected area and its ability to provide sustained support for tissue repair through prolonged growth factor release.
The PLTgel is derived from a patient’s own blood, processed in Syspring’s GTP-compliant cleanroom laboratory into a stable lyophilized powder. This allows for long-term room-temperature storage, increasing flexibility in treatment scheduling.
Spirit Scientific botech, established in 2015 and listed on the emerging stock market in December 2024, reported significant revenue growth. The company anticipates continued momentum in 2025, driven by expanded applications in various medical fields and the launch of new products like PLTgel and platelet-derived exosome lyophilized preparations. Syspring’s primary product remains its PLT lyophilized preparation service, with PLTgel launched in August last year and exosome services introduced in February this year.
Source: 【環球生技】https://news.gbimonthly.com/tw/article/show.php?num=75642
